ProShare Advisors
TCRX icon

ProShare Advisors’s TScan Therapeutics TCRX Stock Holding History

ProShare Advisors’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,626
Closed -$14.7K – 2181
2025
Q1 		$14.7K Sell
10,626
-2,514
-19% -$5.44K ﹤0.01% 2050
2024
Q4 		$39.9K Buy
+13,140
New +$59.6K ﹤0.01% 2207

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

ProShare Advisors's TCRX Position: Q2 2025 in Review

ProShare Advisors sold out of TScan Therapeutics (TCRX) in Q2 2025, closing a stake of 10,626 shares — an estimated $14.7K sold.

ProShare Advisors first reported a position in TCRX in Q4 2024 and held it in 2 quarters. The position peaked at $39.9K in Q4 2024. 81 funds tracked by Wall St. Rank hold TCRX as of Q2 2025.

  • ProShare Advisors reported no remaining TScan Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 10,626 TScan Therapeutics shares in Q2 2025, an estimated $14.7K.
  • ProShare Advisors first reported a position in TScan Therapeutics in Q4 2024 and held it in 2 quarters.
  • ProShare Advisors's TScan Therapeutics position peaked at $39.9K in Q4 2024.
  • 81 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.